WO1991002062A3 - Domaine externe du c-erbb-2: gp75 - Google Patents

Domaine externe du c-erbb-2: gp75 Download PDF

Info

Publication number
WO1991002062A3
WO1991002062A3 PCT/US1990/004340 US9004340W WO9102062A3 WO 1991002062 A3 WO1991002062 A3 WO 1991002062A3 US 9004340 W US9004340 W US 9004340W WO 9102062 A3 WO9102062 A3 WO 9102062A3
Authority
WO
WIPO (PCT)
Prior art keywords
erbb
polypeptides
disclosed
proteins
useful
Prior art date
Application number
PCT/US1990/004340
Other languages
English (en)
Other versions
WO1991002062A2 (fr
Inventor
Susan G Stuart
John J Monahan
Beatrice Claudia Langton
Miriam E C Hancock
Lorrine A Chao
Peter Bluford
Original Assignee
Triton Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23540312&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO1991002062(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Triton Biosciences Inc filed Critical Triton Biosciences Inc
Priority to EP90914094A priority Critical patent/EP0444181B2/fr
Priority to DK90914094T priority patent/DK0444181T3/da
Priority to DE69033842T priority patent/DE69033842T2/de
Priority to CA002042064A priority patent/CA2042064C/fr
Priority to AT90914094T priority patent/ATE207958T1/de
Publication of WO1991002062A2 publication Critical patent/WO1991002062A2/fr
Publication of WO1991002062A3 publication Critical patent/WO1991002062A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5748—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncogenic proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G01N2400/02—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates involving antibodies to sugar part of glycoproteins

Abstract

Sont présentées des méthodes et des compostions pour identifier des tumeurs malignes qui surexpriment l'oncogène C-erbB-2. Des essais utiles pour le diagnostic et le pronostic des maladies néoplastiques sont fournis, lesquels détectent le domaine externe de C-erbB-2, la glycoprotéine gp75 et quantifient le niveau de gp75 dans les liquides biologiques des mammifères porteurs d'une tumeur. Sont ensuite présentés des nouvelles protéines et des polypeptides qui sont recombinants, produits de manière synthétique ou biologique et qui sont codés par la séquence d'ADN de domaine externe de l'oncogène C-erbB-2 (le gène gp75 ou des fragments de celui-ci). Ces types de protéines gp75 et de polypeptides sont utiles comme vaccins, et de manière thérapeutique dans le traitement du cancer soit tout seul, soit en association avec des agents de chimiothérapie. Sont également présentés des anticorps dressés contre ces protéines gp75 et les polypeptides concernés, lesquels sont utiles pour le diagnostic et pour la thérapie. Pour terminer, sont présentés des ensembles d'essai qui illustrent et reprennent les essais de cette invention.
PCT/US1990/004340 1989-08-04 1990-08-02 Domaine externe du c-erbb-2: gp75 WO1991002062A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP90914094A EP0444181B2 (fr) 1989-08-04 1990-08-02 Domaine externe du c-erbb-2: gp75
DK90914094T DK0444181T3 (da) 1989-08-04 1990-08-02 C-erbB-2 eksternt domæne: gp75
DE69033842T DE69033842T2 (de) 1989-08-04 1990-08-02 Äusserliche domäne von c-erbb-2:gp75
CA002042064A CA2042064C (fr) 1989-08-04 1990-08-02 C-erbb-2 domaine exterieur : gp75
AT90914094T ATE207958T1 (de) 1989-08-04 1990-08-02 Äusserliche domäne von c-erbb-2:gp75

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38992089A 1989-08-04 1989-08-04
US389,920 1989-08-04

Publications (2)

Publication Number Publication Date
WO1991002062A2 WO1991002062A2 (fr) 1991-02-21
WO1991002062A3 true WO1991002062A3 (fr) 1991-06-13

Family

ID=23540312

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1990/004340 WO1991002062A2 (fr) 1989-08-04 1990-08-02 Domaine externe du c-erbb-2: gp75

Country Status (10)

Country Link
US (2) US20020155527A1 (fr)
EP (2) EP0444181B2 (fr)
JP (2) JP3859695B2 (fr)
AT (1) ATE207958T1 (fr)
AU (1) AU645760B2 (fr)
CA (1) CA2042064C (fr)
DE (1) DE69033842T2 (fr)
DK (1) DK0444181T3 (fr)
ES (1) ES2166352T3 (fr)
WO (1) WO1991002062A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8940302B2 (en) 2007-03-02 2015-01-27 Genentech, Inc. Predicting response to a HER inhibitor
US9327023B2 (en) 2011-10-25 2016-05-03 The Regents Of The University Of Michigan HER2 targeting agent treatment in non-HER2-amplified cancers having HER2 expressing cancer stem cells

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989006692A1 (fr) * 1988-01-12 1989-07-27 Genentech, Inc. Procede de traitement de cellules tumorales par inhibition de la fonction receptrice du facteur de croissance
EP0474727B1 (fr) * 1989-05-19 1997-07-23 Genentech, Inc. Domaine extracellulaire de her2
JP2895105B2 (ja) * 1989-09-14 1999-05-24 株式会社ニチレイ ｃ‐ｅｒｂＢ‐２癌遺伝子産物をイムノアッセイする乳癌の血清診断法とそのキット
IE910820A1 (en) 1990-03-22 1991-09-25 Sloan Kettering Inst Cancer Gp75 as a tumor vaccine for melanoma
US5801005A (en) * 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
US6953573B1 (en) 1993-03-17 2005-10-11 University Of Washington Compounds for eliciting or enhancing immune reactivity to HER-2/neu protein for prevention or treatment of malignancies in which the HER-2/neu oncogene is associated
US5869445A (en) * 1993-03-17 1999-02-09 University Of Washington Methods for eliciting or enhancing reactivity to HER-2/neu protein
EP0616812B1 (fr) * 1993-03-24 1999-11-03 Berlex Biosciences Combinaison d'agents anti-hormonause et molécules de liaison pour le traitement du cancer
IT1264083B1 (it) * 1993-12-10 1996-09-10 Enea Ente Nuove Tec Procedimento per la produzione in piante di anticorpi ingegnerizzati, anticorpi prodotti e loro uso in diagnosi e terapia.
US5783404A (en) * 1995-04-13 1998-07-21 Amgen Inc. Methods and compositions for determining HER-2/neu expression using monoclonal antibodies
US5759776A (en) * 1995-06-05 1998-06-02 California Pacific Medical Center Targets for breast cancer diagnosis and treatment
US6586570B1 (en) 1996-01-11 2003-07-01 Corixa Corporation Compositions and methods for the treatment and diagnosis of breast cancer
US7241876B2 (en) 1996-01-11 2007-07-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
EP0874902A2 (fr) * 1996-01-11 1998-11-04 Corixa Corporation Compositions et procedes pour le traitement et le diagnostic du cancer du sein
US6828431B1 (en) 1999-04-09 2004-12-07 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US6656480B2 (en) 1996-01-11 2003-12-02 Corixa Corporation Compositions and methods for the treatment and diagnosis of breast cancer
US6861506B1 (en) 1996-01-11 2005-03-01 Corixa Corporation Compositions and methods for the treatment and diagnosis of breast cancer
US6423496B1 (en) 1996-01-11 2002-07-23 Corixa Corporation Compositions and methods for the treatment and diagnosis of breast cancer
US6225054B1 (en) 1996-01-11 2001-05-01 Corixa Corporation Compositions and methods for the treatment and diagnosis of breast cancer
US6344550B1 (en) 1996-01-11 2002-02-05 Corixa Corporation Compositions and methods for the treatment and diagnosis of breast cancer
AU2452197A (en) * 1996-04-10 1997-10-29 California Pacific Medical Center Genes amplified in cancer cells
US5776683A (en) * 1996-07-11 1998-07-07 California Pacific Medical Center Methods for identifying genes amplified in cancer cells
US7371376B1 (en) 1996-10-18 2008-05-13 Genentech, Inc. Anti-ErbB2 antibodies
AU747577B2 (en) 1997-01-30 2002-05-16 Novartis Vaccines And Diagnostics, Inc. Use of microparticles with adsorbed antigen to stimulate immune responses
ZA982968B (en) * 1997-04-09 1998-10-27 Corixa Corp Compositions and methods for the treatment and diagnosis of breast cancer
ZA9811162B (en) 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
US7396810B1 (en) 2000-08-14 2008-07-08 Oregon Health Sciences University Compositions and methods for treating cancer by modulating HER-2 and EGF receptors
US7393823B1 (en) 1999-01-20 2008-07-01 Oregon Health And Science University HER-2 binding antagonists
US7625859B1 (en) 2000-02-16 2009-12-01 Oregon Health & Science University HER-2 binding antagonists
US7198920B1 (en) 1999-01-29 2007-04-03 Corika Corporation HER-2/neu fusion proteins
US6294349B1 (en) * 1999-03-01 2001-09-25 University Of Mississippi Medical Ctr. Method of diagnosing and monitoring malignant breast carcinomas
US7566452B1 (en) 1999-05-04 2009-07-28 New York University Cancer treatment with endothelin receptor antagonists
AUPQ105799A0 (en) * 1999-06-18 1999-07-08 Victor Chang Cardiac Research Institute, The Cell growth inhibition
DK1189634T3 (da) * 1999-06-25 2007-06-25 Genentech Inc Behandling af prostatacancer med anti-ErbB2-antistoffer
US20030086924A1 (en) * 1999-06-25 2003-05-08 Genentech, Inc. Treatment with anti-ErbB2 antibodies
US7041292B1 (en) 1999-06-25 2006-05-09 Genentech, Inc. Treating prostate cancer with anti-ErbB2 antibodies
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
EP1280923A2 (fr) * 2000-04-28 2003-02-05 Millennium Pharmaceuticals, Inc. 14094, un nouveau membre dans la famille de la trypsine humaine et son utilisation
SI1282443T1 (sl) 2000-05-19 2010-01-29 Genentech Inc Metoda detekcije gena za izboljšanje verjetnosti učinkovitega odziva na terapijo raka z antagonistom ErbB
US7229623B1 (en) 2000-08-03 2007-06-12 Corixa Corporation Her-2/neu fusion proteins
DE60236864D1 (de) 2001-05-31 2010-08-12 Novartis Vaccines & Diagnostic Chimere alphavirus-replikon-partikel
US7919098B2 (en) 2002-03-26 2011-04-05 Zensun ( Shanghai ) Sci & Tech Co., Ltd. ErbB-3 based methods and compositions for treating neoplasms
CA2506320A1 (fr) * 2002-11-21 2004-06-10 Genentech, Inc. Therapie de maladies ou troubles benins a l'aide d'anticorps anti-erbb2
WO2005016966A2 (fr) * 2003-05-16 2005-02-24 Receptor Biologix, Inc. Proteines hybrides a intron et procede d'identification et d'utilisation de celles-ci
EP1745073A2 (fr) * 2004-05-14 2007-01-24 Receptor Biologix, Inc. Isoformes de recepteurs de la surface cellulaire et methodes d'identification et d'utilisation de ces derniers
EP2277595A3 (fr) 2004-06-24 2011-09-28 Novartis Vaccines and Diagnostics, Inc. Composés pour potentialiser l'immunité
WO2006115509A2 (fr) 2004-06-24 2006-11-02 Novartis Vaccines And Diagnostics Inc. Immuno-potentialisateurs a petites molecules et analyses visant a detecter leur presence
WO2006042002A2 (fr) * 2004-10-05 2006-04-20 Oregon Health And Science University Compositions et procedes de traitement de maladie
CA2592177A1 (fr) 2005-01-21 2006-07-27 Genentech, Inc. Dosage fixe d'anticorps anti-her
BRPI0606542A8 (pt) * 2005-02-23 2018-03-20 Genentech Inc métodos para aumentar o tempo de progressão de uma doença (ttp)
JP2006316040A (ja) 2005-05-13 2006-11-24 Genentech Inc Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法
EP2357000A1 (fr) 2005-10-18 2011-08-17 Novartis Vaccines and Diagnostics, Inc. Immunisations mucosiques et systémiques avec des particules de réplicon à alpha-virus
EP2357184B1 (fr) 2006-03-23 2015-02-25 Novartis AG Composés d'imidazoquinoxaline en tant qu'immunomodulateurs
US9551033B2 (en) 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
CA3006428A1 (fr) * 2007-06-08 2008-12-18 Genentech, Inc. Marqueurs d'expression de gene de resistance tumorale a un traiteme r inhibiteur her2
WO2009003082A2 (fr) * 2007-06-26 2008-12-31 Vanderbilt University Compositions immunologiques utilisées en tant que biomarqueurs et/ou agents thérapeutiques pour le cancer
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
US8585505B2 (en) 2008-12-15 2013-11-19 Tetris Online, Inc. Inter-game interactive hybrid asynchronous computer game infrastructure
US20120121596A1 (en) 2009-03-20 2012-05-17 Germaine Fuh Bispecific anti-her antibodies
WO2010136569A1 (fr) 2009-05-29 2010-12-02 F. Hoffmann-La Roche Ag Modulateurs de la signalisation her2 chez des patients exprimant her2 souffrant d'un cancer de l'estomac
MY160556A (en) 2010-02-18 2017-03-15 Genentech Inc Neuregulin antagonists and use thereof in treating cancer
WO2011146568A1 (fr) 2010-05-19 2011-11-24 Genentech, Inc. Prédiction de réponses à un inhibiteur de her
EP2643353A1 (fr) 2010-11-24 2013-10-02 Novartis AG Molécules multi-spécifiques
SG191153A1 (en) 2010-12-23 2013-07-31 Hoffmann La Roche Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
BR112014003431A2 (pt) 2011-08-17 2017-06-13 Genentech Inc anticorpo, ácido nucleico, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, agente farmacêutico, uso do anticorpo, método de tratamento de um indivíduo que tem câncer e método de aumento de tempo para recorrência de tumor
CN104271761B (zh) 2011-11-30 2017-03-15 霍夫曼-拉罗奇有限公司 癌症中的erbb3突变
EP2788500A1 (fr) 2011-12-09 2014-10-15 F.Hoffmann-La Roche Ag Identification de non-répondeurs aux inhibiteurs de her2
JP2015514710A (ja) 2012-03-27 2015-05-21 ジェネンテック， インコーポレイテッド Ｈｅｒ３阻害剤に関する診断及び治療
KR102291355B1 (ko) 2012-11-30 2021-08-19 에프. 호프만-라 로슈 아게 Pd-l1 억제제 공동치료를 필요로 하는 환자의 식별방법
WO2017194554A1 (fr) 2016-05-10 2017-11-16 Inserm (Institut National De La Sante Et De La Recherche Medicale) Polythérapies pour le traitement du cancer

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62108157A (ja) * 1985-11-06 1987-05-19 Ajinomoto Co Inc 抗体
WO1987007646A2 (fr) * 1986-06-04 1987-12-17 Whitehead Institute For Biomedical Research Detection de mutations ponctuelles dans des genes neu

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6054561A (en) * 1984-02-08 2000-04-25 Chiron Corporation Antigen-binding sites of antibody molecules specific for cancer antigens
US5169774A (en) * 1984-02-08 1992-12-08 Cetus Oncology Corporation Monoclonal anti-human breast cancer antibodies
WO1989006692A1 (fr) * 1988-01-12 1989-07-27 Genentech, Inc. Procede de traitement de cellules tumorales par inhibition de la fonction receptrice du facteur de croissance
EP0474727B1 (fr) * 1989-05-19 1997-07-23 Genentech, Inc. Domaine extracellulaire de her2
US6197855B1 (en) * 1998-09-29 2001-03-06 Solutia Inc. Nucleation of Polyamides in the presence of hypophosphite

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62108157A (ja) * 1985-11-06 1987-05-19 Ajinomoto Co Inc 抗体
WO1987007646A2 (fr) * 1986-06-04 1987-12-17 Whitehead Institute For Biomedical Research Detection de mutations ponctuelles dans des genes neu

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
"Symposia on Molecular and cellular Biology", CELL.BIOCHEM, 8 February 1990 (1990-02-08), XP002352600 *
B.M.SEFTON: "Neus about c-erb-B-2 and HER2", TRENDS GENET, vol. 4, no. 9, September 1988 (1988-09-01), pages 247 - 248, XP002988523 *
C.I.BARGMANN ET AL: "The neu oncogene encodes an epidermal growth factor receptor-related protein", NATURE, vol. 319, no. 6050, 16 January 1986 (1986-01-16), XP001024206 *
CHEMICAL ABSTRACTS, vol. 107, no. 19, 1987, Columbus, Ohio, US; abstract no. 174203M, page 570; XP002988525 *
S.KARGER (BASEL,CH), K.M. PRICE ET AL: "The production and Characterisation of monoclonal antibodies to myc, c-erbB-2 and EGF-receptor using a synthetic peptide approach", SYMPOSIUM ON MONOCLONAL ANTIBODIES FOR THERAPY, PREVENTION AND IN VIVO DIAGNOSIS OF HUMAN DISEASE, UTRECHT, 19 May 1989 (1989-05-19), UTRECHT, pages 23 - 32, XP002988526 *
T.YAMAMOTO ET AL: "Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor", NATURE, vol. 319, no. 6050, 16 January 1986 (1986-01-16), pages 230 - 234, XP002095983 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8940302B2 (en) 2007-03-02 2015-01-27 Genentech, Inc. Predicting response to a HER inhibitor
US9327023B2 (en) 2011-10-25 2016-05-03 The Regents Of The University Of Michigan HER2 targeting agent treatment in non-HER2-amplified cancers having HER2 expressing cancer stem cells

Also Published As

Publication number Publication date
EP1006194A2 (fr) 2000-06-07
EP1006194A3 (fr) 2008-07-02
AU645760B2 (en) 1994-01-27
CA2042064C (fr) 2008-10-21
ES2166352T3 (es) 2002-04-16
DE69033842D1 (de) 2001-12-06
EP0444181A1 (fr) 1991-09-04
US20060019344A1 (en) 2006-01-26
CA2042064A1 (fr) 1991-02-05
EP0444181B2 (fr) 2010-11-24
JPH04503012A (ja) 1992-06-04
JP2006304807A (ja) 2006-11-09
EP0444181B1 (fr) 2001-10-31
ATE207958T1 (de) 2001-11-15
JP3859695B2 (ja) 2006-12-20
US20020155527A1 (en) 2002-10-24
WO1991002062A2 (fr) 1991-02-21
AU6413590A (en) 1991-03-11
DE69033842T2 (de) 2002-06-20
DK0444181T3 (da) 2002-02-25

Similar Documents

Publication Publication Date Title
WO1991002062A3 (fr) Domaine externe du c-erbb-2: gp75
CA2131826A1 (fr) Gene mn et proteine
WO2001055343A8 (fr) Acides nucleiques, proteines et anticorps
WO2002000677A8 (fr) Acides nucleiques, proteines et anticorps
WO1998010069A3 (fr) Proteine e25a, ses procedes de production et d'utilisation
DE69126038T2 (de) Diagnose von krebs-metastasen durch das mts-1 gen
EP0833948A4 (fr) Gene et proteine specifiques du colon
PT1299727E (pt) Novo antigénio tumoral útil em diagnóstico e terapia de cancros da bexiga, do ovário, do pulmão e do rim
WO2001055300A8 (fr) Acides nucleiques, proteines et anticorps
EP1243653A3 (fr) Protéine E25a, procédés de production et utilization
WO2001055313A8 (fr) Acides nucleiques, proteines et anticorps
WO2001055329A3 (fr) Acides nucleiques, proteines et anticorps

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB IT LU NL SE

WWE Wipo information: entry into national phase

Ref document number: 2042064

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1990914094

Country of ref document: EP

AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB IT LU NL SE

WWP Wipo information: published in national office

Ref document number: 1990914094

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1990914094

Country of ref document: EP